Skip to main content

Table 5 Treatments and outcomes

From: Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma

Patients Treatment1 PFS1 Treatment2 PFS2 Treatment3 PFS3 Treatment 4 PFS3 Treatment5 PFS4 Outcomes OS
1 Surgery 1 m Atezo 2w dead 1.5 m
2 TP 3 × 21d Gefitinib 2w Apatinib 1 m dead 4.1 m
3 TP 2 × 21d T 1 × 21d T + Nivo 1 × 21d dead 3 m
4 TP 21d          dead 1.5 m
5 RT 1 m Pembro 7 × 21d(5 m) Support care 13 m dead 19.5 m
6 Cet + DP + CCR 6 × 21d Support care 18 m Pembro+Cet 4 × 21d Pembro+ oxaliplatin 1 × 21d Support care dead 26.7 m
7 DP + Cet 2 × 21d G + T + Nivo
Pembro+Nivo+GT
2w
2 × 14d
Nivo+Iri + P 21d Pembro+CBP + R 3 m Support care Alive 12 m+
  1. TP paclitaxel-albumin(T)+carboplatin, DP docetaxel(D) + platinum, Cet cetuximab, Nivo nivotuzumab, CCR concurrent chest radiotherapy(RT), Atezo atezolizumab, Pembro pembrolizumab, Iri irinotecan